TITLE

Introduction to the Third World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy)

AUTHOR(S)
RAZ, ITAMAR; DEL PRATO, STEFANO
PUB. DATE
May 2011
SOURCE
Diabetes Care;May2011 Supplement 2, Vol. 34, pS99
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The section introduces several articles presented within the May 2011 supplement of "Diabetes Care," including a description of the regulations of the U.S. Food and Drug Administration for cardiovascular safety outcome studies, prevention and treatment of type 2 diabetes in children, and a debate over the prescription of renin-angiotensin system to diabetic patient.
ACCESSION #
61967993

 

Related Articles

  • Impact of the U.S. Food and Drug Administration Cardiovascular Assessment Requirements on the Development of Novel Antidiabetes Drugs. HIRSHBERG, BOAZ; RAZ, ITAMAR // Diabetes Care;May2011 Supplement 2, Vol. 34, pS101 

    The article examines the drivers for the regulations of the U.S. Food and Drug Administration related to cardiovascular (CV) safety of type 2 diabetes treatments as well as its impact on the development of novel anti-diabetes drugs. According to results of outcome studies, a surrogate biomarker...

  • Model-Based Benefit–Risk Assessment: Can Archimedes Help? Krishna, R. // Clinical Pharmacology & Therapeutics;Mar2009, Vol. 85 Issue 3, p239 

    In December 2008, the US Food and Drug Administration issued a new draft Guidance for Industry on Diabetes Mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat Type 2 diabetes. This guidance comes at a time when recent discussions have focused on delineation of...

  • Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus. Kapoor, Karan; George, Praveen; Miller, Michael // Cardiology;Sep2016, Vol. 135 Issue 2, p108 

    Objectives: To review the spectrum of contemporary cardiovascular outcomes trials (CVOTS) in type 2 diabetes mellitus (T2DM), spanning both the pre- and post-ACCORD eras. Methods: We reviewed a total of 12 CVOTs and delineated the two eras in accordance with the 2008 US Food and Drug...

  • FDA approved expanded indication for exenatide.  // Hem/Onc Today;12/10/2009, Vol. 10 Issue 23, p74 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) in December 2009 for exenatide injection for use as monotherapy in patients with type 2 diabetes.

  • Bydureon takes on diabetes. DEARMENT, ALARIC // Drug Store News;3/12/2014, Vol. 34 Issue 4, p44 

    The article reports on the approval of the drug Bydureon by the U.S. Food and Drug Administration (FDA) for the treatment of Type 2 diabetes.

  • FDA's first active medical product surveillance eyes antidiabetic-MI link. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/1/2011, Vol. 68 Issue 7, p550 

    The article reports that Food and Drug Administration's (FDA's) first electronic active surveillance system will be used to gauge the risk of myocardial infarction (MI) in type 2 diabetes patients using saxagliptin. The analysis will be conducted ahead of a Phase IV study sponsored by...

  • Bromocriptine in Diabetes Mellitus - A Review. Pandita, Aakriti; Azher, Idrees // Asian Student Medical Journal;2013, Vol. 13 Issue 6, p1 

    The article presents information on the approval of the drug QR-bromocriptine by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. It mentions that the drug is an antidiabetic that helps in reducing plasma glucose, triglycerides and cardiovascular events....

  • FDA restricts access to Avandia due to increased cardiovascular risks.  // Drug Topics;Oct2010, Vol. 154 Issue 10, p21 

    The article focuses on the regulatory move of the U.S. Food and Drug Administration (FDA) in restricting the use of formulations that contain rosiglitazone to patients with Type 2 diabetes. It mentions that FDA's new restriction is a response on the growing risk of cardiovascular events on...

  • Byetta.  // Formulary;Feb2007, Vol. 42 Issue 2, p80 

    The article reports on the approval of the exenatide as adjunctive therapy to improve glycemic control in patients with type 2 diabetes not adequately controlled by a thizolidinedione by the U.S. Food and Drug Administration (FDA). Exenatide has been approved by the FDA after its effectiveness...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics